Characterization of grass carp (Ctenopharyngodon idella) beta-defensin 1: implications for its role in inflammation control.

Considering that fish grows in a complex aquatic environment, there is an increasing interest in fish ß-defensins, which is an important group of antimicrobial peptides (AMPs). In this study, grass carp (Ctenopharyngodon idella) ß-defensin 1 (gcdefb1) was isolated using homology cloning technology. Tissue distribution assay showed that gcdefb1 transcripts were expressed with the highest levels in brain and liver, followed by some mucous tissues. To examine gcDefb1 bioactivities, the recombinant gcDefb1 proteins fused with thioredoxin tag protein (Trx) (Trx-Defb1) were induced for production in Escherichia coli Rosetta-gami2(DE3)pLysS under optimal expression conditions. The antibacterial activity of Trx-Defb1 against Aeromonas hydrophila was assessed and its minimum inhibitory concentration (MIC) was 36 µM. Interestingly, Trx-Defb1 significantly inhibited LPS-induced Tnf-α (gcTnf-α) secretion and nitric oxide production in grass carp head kidney monocytes/macrophages (HKM), although Trx-Defb1 alone had no effect. Our studies provide the first evidence of fish ß-defensin 1 engaging in both antimicrobial and inflammation suppression process.

Pediatric adrenocortical carcinoma: clinical features and application of neoadjuvant chemotherapy.

OBJECTIVE: To summarize the clinical characteristics of children with adrenocortical carcinoma (ACC) and preliminarily explore the indications for and efficacy of neoadjuvant chemotherapy in certain patients. METHODS: The data of 49 children with adrenocortical tumors (ACT) in the past 15 years were retrospectively analyzed, and after pathology assessment using Weiss system grading, 40 children diagnosed with ACC were included. Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and three-dimensional (3D) reconstruction of contrast-enhanced computed tomography data were used to evaluate the response to neoadjuvant chemotherapy. RESULTS: Forty patients (17 males, 23 females) with ACC were enrolled. Abnormal hormone levels were common in children with ACC (n = 31), and in terms of clinical presentation, sexual precocity was the most common (n = 14, 35.0%), followed by Cushing's syndrome (n = 12, 30.0%). Seven of 40 children received neoadjuvant chemotherapy due to a maximum lesion diameter greater than 10 cm (n = 4), invasion of surrounding tissues (n = 2), intravenous tumor thrombus (n = 2), and/or distant metastasis (n = 2); 2 patients achieved partial response, and 5 had stable disease according to the RECIST 1.1 standard. Furthermore, 3D tumor volume reconstruction was performed in 5 children before and after neoadjuvant chemotherapy. Tumor volumes were significantly reduced in all 5 children, with a median volume reduction of 270 (interquartile range, IQR 83, 293) (range: 49-413) ml. After surgery with/without chemotherapy, the 5-year overall survival rate for all children was 90.0% (95% CI-confidence interval 80.0-100.0%), and the 5-year event-free survival rate was 81.5% (95% CI 68.0-97.7%). CONCLUSION: In the diagnosis and treatment of pediatric ACC, a comprehensive endocrine evaluation is necessary to facilitate early diagnosis. Surgery and chemotherapy are important components of ACC treatment, and neoadjuvant chemotherapy should be considered for children with ACC who meet certain criteria, such as a large tumor, distant metastases, or poor general condition.